Courtney Flaherty

Courtney Flaherty joined OncLive as an assistant editor in October 2022. Leveraging an educational background in the life sciences and prior experience conducting interviews in a university setting, she plays a key role in shaping social media strategy, covering live conferences, and producing multimedia content for both print and digital platforms. Email: cflaherty@onclive.com

Articles

Bezuclastinib Plus Sunitinib Shows PFS Benefit in Second-Line GIST

November 10th 2025

The phase 3 PEAK trial met its primary PFS end point with bezuclastinib plus sunitinib in imatinib-resistant/intolerant gastrointestinal stromal tumors.

Evolving Post–CDK4/6 Inhibitor Strategies Reflect Need for Precision Approaches in HR+ Breast Cancer

November 10th 2025

Kevin Kalinsky, MD, MS, FASCO, discusses treatments and targeted therapies in the post–CDK4/6 inhibitor setting of HR+ breast cancer.

Giredestrant/Everolimus Opens Doors for Improved SERD Regimens for ER+, Endocrine-Resistant Breast Cancer

November 7th 2025

Erica L. Mayer, MD, MPH, discusses data with giredestrant and how the evERA trial shows the potential for SERD-based regimens in ER-positive breast cancer.

First-Line Sacituzumab Govitecan After Endocrine Therapy Fails to Improve PFS in HR+/HER2-Negative Breast Cancer

November 7th 2025

The phase 3 ASCENT-07 trial did not meet its primary PFS end point with first-line sacituzumab govitecan in hormone receptor–positive, HER2-negative breast cancer.

FDA Approves Generic Dasatinib Tablets for CML, ALL

November 7th 2025

The FDA has approved generic dasatinib tablets for select patients with chronic myeloid leukemia and acute lymphoblastic leukemia.

Dr Jakubowiak on the ATLAS Trial of Carfilzomib, Lenalidomide, and Dexamethasone in Myeloma

November 6th 2025

Andrzej Jakubowiak, MD, PhD, discusses the rationale of the phase 3 ATLAS study in patients with multiple myeloma.

Dr Yuan on the Potential Benefit of Upfront T-DXd in HER2+ Breast Cancer With CNS Metastases

November 6th 2025

Yuan Yuan, MD, PhD, discusses questions regarding the potential benefit of T-DXd in first line regimens for HER2-positive breast cancer with CNS metastases.

GFH375 Yields Responses, Disease Control in Heavily Pretreated KRAS G12D+ PDAC

November 6th 2025

GFH375 produced responses and tumor shrinkage in heavily pretreated pancreatic ductal adenocarcinoma harboring KRAS G12D mutations.

FDA Adds REMS Guidelines for Pexidartinib in Tenosynovial Giant Cell Tumor

November 5th 2025

The FDA has added REMS guidelines for the use of pexidartinib in tenosynovial giant cell tumor.

Immune-Modulatory and mRNA-Based Cancer Vaccines Could Boost Benefit With ICIs Across Solid Tumors

November 5th 2025

Three experts spotlight key trials from the 2025 ESMO Congress investigating novel cancer vaccines across solid tumors.

Dr Colombo on the Rationale for Evaluating Pembrolizumab Plus Paclitaxel With/Without Bevacizumab in PROC

November 4th 2025

Nicoletta Colombo, MD, PhD, discusses the rationale for evaluating pembrolizumab plus weekly paclitaxel with/without bevacizumab in recurrent PROC.

Positive KEYNOTE-B96 Data Show Role for Immunotherapy–Based Regimens in PROC

November 4th 2025

Nicoletta Colombo, MD, PhD, discusses clinical implications for integrating immunotherapy into the treatment arsenal for platinum-resistant ovarian cancer.

Vispa-Cel Shows Comparable Efficacy, Durability to Autologous CAR T-Cell Therapy in R/R B-Cell NHL

November 4th 2025

In the phase 1 ANTLER study, vispa-cel demonstrated ORRs of 82% and 86% among patients in the confirmatory and optimized cohorts, respectively.

China’s Center for Drug Evaluation Grants Breakthrough Therapy Designation to Ivonescimab in TNBC

November 4th 2025

Ivonescimab plus chemotherapy has received breakthrough therapy designation as first-line therapy in patients with triple-negative breast cancer.

ADC and CDK4/6 Inhibitor Research Set to Refine TNBC and ER+ Breast Cancer Treatment Strategies

November 4th 2025

Yuan Yuan, MD, PhD, discusses the use of sacituzumab govitecan in TNBC and remaining questions about the use of CDK4/6 inhibitors in ER-positive disease.

Adjuvant Ribociclib Plus AI Therapy Shows More Pronounced iDFS Benefit After 5 Years in HR+, HER2-Negative Early Breast Cancer

November 4th 2025

Sara A. Hurvitz, MD, FACP, unpacks data with adjuvant ribociclib plus endocrine therapy from the 5-year prespecified analysis of the NATALEE trial.

Dr Sweis on Next Steps for the Investigation of XmAb819 in RCC and Beyond

October 31st 2025

Randy F. Sweis, MD, explains future avenues for the investigation for XmAb819 in tumor types beyond renal cell carcinoma.

Dr Hurvitz on Data With Gedatolisib-Based Regimens in PIK3CA Wild-Type HR+/HER2-Negative Breast Cancer

October 30th 2025

Sara A. Hurvitz, MD, FACP, shares efficacy and safety data from the VIKTORIA-1 study in endocrine-resistant HR-positive breast cancer.

Dr Yuan on the DEMETHER Trial of Induction T-DXd Plus HP Maintenance in HER2+ Breast Cancer

October 30th 2025

Yuan Yuan, MD, PhD, discusses a new treatment approach involving induction T-DXd followed by trastuzumab/pertuzumab maintenance in HER2-positive disease.

Dr Hurvitz on the Rationale for Targeting PI3K and mTOR in PIK3CA Wild-Type HR+/HER2-Negative Breast Cancer

October 30th 2025

Sara A. Hurvitz, MD, FACP, explains the clinical rationale for targeting the PI3K/mTOR pathways with gedatolisib in the VIKTORIA-1 trial.